Skip to main content
. Author manuscript; available in PMC: 2017 Jul 14.
Published in final edited form as: J Med Chem. 2016 Jun 17;59(13):6136–6148. doi: 10.1021/acs.jmedchem.6b00040

Table 3.

Antiviral screening and biochemical assay of scaffold analogues 52–55

Compd Structure Antiviral Screening (10 μM)a
 INST IC50
CPE reduction % viability % (μM)b
52 graphic file with name nihms-795969-t0030.jpg 6.5 10 >100
53 graphic file with name nihms-795969-t0031.jpg 0 89 7.0 ± 3.3
54 graphic file with name nihms-795969-t0032.jpg 26 100 37 ± 21
55 graphic file with name nihms-795969-t0033.jpg 0 5.5 0.43 ± 0.13
a

Cytoprotection assay using HIV-1 IIIB in CEM-SS cells with a viral control for CPE reduction and cell control for cell viability.

b

Concentration inhibiting INST by 50%, expressed as mean ± standard deviation from at least three independent experiments.